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CLINICAL PRACTICE
A review of the current literature shows pethidine (meperidine)
use to be less favourable than commonly thought. When first
synthesised in the 1930s, it was prematurely lauded as a
substitute for morphine, and marketed as a drug lacking many
of the adverse effects such as respiratory depression, urinary
retention, constipation and chemical dependency typical of
opioids such as morphine. None of these claims has been
substantiated1 by clinical evidence; in fact pethidine carries
additional risks that ensure its declining use internationally.1,2
These risks, and the evidence questioning its analgesic efficacy,
make it necessary to review its continued popular use in South
Africa.
Pethidine is typically used for management of moderate to
severe pain.2 At best, dose for dose, it may be as good as
morphine. Studies have been conducted in a variety of settings,
most commonly postoperatively or intrapartum, or they have
investigated patient-controlled analgesia, but there remains no
conclusive evidence that pethidine is a better or safer
alternative to morphine in any setting.1,3-6
Pethidine is metabolised by the liver into a variety of
metabolites, most important of which is the active metabolite,
norpethidine. Norpethidine is neurotoxic with epileptogenic
potential. Pethidine has a plasma half-life of 2.5 - 4 hours, with
a similar duration of analgesic effect. Norpethidine on the
other hand has a considerably longer plasma half-life of
between 14 and 21 hours — which is further prolonged in
patients with renal or hepatic dysfunction.2,6,7 Norpethidine has
approximately half the analgesic effect of pethidine,2 and this,
coupled with pethidine’s short plasma half-life, results in
repeated doses of pethidine being required to manage pain.
This multiple dosing leads to accumulation of the harmful
metabolite, norpethidine, increasing the potential for a
neurological adverse event.
The neurotoxicity of norpethidine results in a range of
symptoms, from irritability, restlessness and agitation
(potentially mistaken as pain) to tremors, gross jerking,
confusion and seizures. The mechanism of this neurological
action is related to its ability to increase serotonin and
noradrenalin in the central nervous system.1
Pethidine has the potential to cause the serotonin syndrome
when used concomitantly with other serotonergic agents. The
selective serotonin re-uptake inhibitors and tramadol must be
used with great caution when pethidine is also part of
management, and it is an absolute contraindication to co-
administer pethidine with the monoamine-oxidase inhibitors
(MAOIs); several fatal reactions have been reported. Pethidine
should never be prescribed within a 14-day period of stopping
an MAOI.1,2
Also of note is that commonly used drugs such as
theophylline, tricyclic antidepressants and the fluoroquino-
lones may potentiate pethidine’s seizure potential.6
Pethidine has a vagolytic action, which may lead to
tachycardias or arrhythmias, particularly in patients post
myocardial infarction and in those with supraventricular
tachycardia.2,8 This action of pethidine makes morphine
preferable in the setting of the acute coronary syndrome.
Pethidine is generally used in preference to other opioids in
the treatment of biliary colic or pancreatitis, based on the
historical presumption that morphine causes more biliary
spasm than pethidine.9 Review of the published data revealed
that equivalent doses of pethidine were not used (i.e. 100 mg :
10 mg) in those studies. Relatively lower doses of pethidine
were used, thereby showing it to be less spasmogenic than
morphine. Of note, the sphincter of Oddi is equally sensitive to
all opioids, at equi-analgesic doses.10
Globally there has been a move away from the use of
pethidine.2 Growing awareness of its adverse effects is ensuring
its rational use in updated pain management protocols.1 One
example is the recommendation of the Agency for Health Care
Policy and Research, which states categorically that pethidine
is contraindicated for the treatment of chronic pain. It adds that
pethidine ‘may be used in acute pain situations for very brief
courses in otherwise healthy individuals who have not
demonstrated an unusual reaction (i.e. local histamine release
at the infusion site) or allergic response to other opioids such as
morphine. It is absolutely contraindicated in patients with
renal dysfunction’.9,11 Most recently, in April 2003, the World
Health Organization removed pethidine from the model
essential drugs list stating that ‘morphine is the preferred
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potent opioid’.12
Pethidine also carries a high potential for abuse. A recent
report published in this Journal on substance-abusing doctors
indicates that the drug is highly abused.13 Twenty-five per cent
of all cases of abuse reported to the Medical and Dental
Professions Board involved pethidine. Pethidine addiction by
medical personnel appears to be an occupational hazard.  Easy
availability and access to the drug, and long and stressful
working hours are major contributing factors and when
combined with individual emotional or mental susceptibility,
can lead to addiction.14 Although it is known to occur, there is
much less evidence of pethidine abuse in the general
population. Other opiate abuse, such as that involving heroin
or codeine, is more prevalent.15
In conclusion, popular use of the opioid analgesic pethidine
is perpetuated by familiarity rather than by evidence of its
effectiveness. It has a shorter duration of analgesic action than
morphine;  it produces a neurotoxic metabolite norpethidine
that accumulates due to its longer half-life;  it interacts
dangerously with several drugs;  it has vagolytic potential; and
most importantly, its analgesic efficacy is not superior to that of
other opioids. 
Morphine, therefore, remains the drug of choice in the
setting of moderate to severe pain management.
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IN BRIEF
Gas and other fume-emitting heaters may cause asthma in children
Asthma is one of the most prevalent chronic diseases in childhood, and is globally a major public health problem.  Various
exposures have been suggested as causative or exacerbating factors. These include environmental tobacco smoke, air
pollution and combustion products from fume-emitting appliances as well as indoor and outdoor allergens. Several studies
have shown adverse effects of gas cookers and heaters on respiratory health. The long-term effects of early life exposure to
these appliances is not known. A study was conducted to investigate the effect of exposure to fume-emitting heaters,
currently and during the first year of life, on the risk of asthma outcomes (Thorax 2004; 59: 741-745). A cross-sectional study
of schoolchildren aged 8 - 11 years was conducted in Australia. Information on symptoms and heating types was collected
by parent-completed questionnaire. It emerged from the survey that there was no association between asthma and current
use of fume-emitting heaters. However, having been exposed to fume-emitting heaters during the first year of life was
associated with an increased risk of airway hyper-responsiveness and recent wheeze in later years of childhood. If confirmed
in other settings, this finding would indicate a review of the range of types of heaters appropriate for use where young
children live.
